Skip to main content

Table 1 Characteristics of the study population at time of serum sampling

From: Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study

 

AS (n = 76)

IBD-AS (n = 77)

P-value

Age, y

39.5 (28.5 to 50.5)

39.0 (31.0 to 50.0)

ns

Disease duration, y

5.0 (1.0 to 11.8)

6.0 (1.5 to 11.5)

ns

Male, %

86

78

ns

HLA-B27 positive, %

82

59

0.0033

BASDAI, NRS, 0 to 10

4.2 (2.5 to 6.8)

3.3 (2.4 to 6.7)

ns

BASFI, NRS, 0 to 10)

4.1 (1.4 to 6.4)

3.2 (0.7 to 6.1)

ns

Biologic current, %

24

30

ns

DMARD current, %

11

35

0.0004

Steroid current, %

3

14

0.0173

NSAID current, %

63

39

0.0036

History of uveitis, %

21

31

ns

History of psoriasis, %

7

7

ns

Current smoker, %

28

30

ns

ESR, mm/h

15.7 (3.0 to 25.2)

15.3 (5.3 to 22.5)

ns

CRP, mg/L

6.5 (3.0 to 15.5)

9.0 (3.0 to 19.0)

0.0532

  1. Values are median (IQR) unless stated otherwise. For comparison: mechanical back pain patients (n=48): age 43.0 (34.8 to 53.0) y, 56.3% male, ESR 4.0 (2.0 to 7.5) mm/h, CRP 3.0 (3.0 to 3.0) mg/L. HLA, human leukocyte antigen; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; NRS, numerical rating scale; DMARD, disease modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ns, not significant.